Pharmaceutical

Conduit acquires three first-in-class assets from AstraZeneca 

Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.

Aug 9, 2024 - 04:00
Conduit acquires three first-in-class assets from AstraZeneca 
Conduit plans to advance two assets, AZD1656 and AZD5658, into Phase II testing for autoimmune disorders.
Read the original article

Tags:

Previous Article

CRISPR-based Casgevy is made accessible in England following NICE guidance

Next Article

Pharmacosmos ventures into oncology and merges with G1 Therapeutics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Zealand raises DKr1.45bn to advance obesity pipeline

Zealand raises DKr1.45bn to advance obesity pipeline

Jan 9, 2024

ASH 2024: Regeneron’s Ordspono faces challenges, but positive results signal hope

ASH 2024: Regeneron’s Ordspono faces challenges, but po...

Dec 11, 2024

FDA accepts Deciphera’s vimseltinib NDA for priority review

FDA accepts Deciphera’s vimseltinib NDA for priority re...

Aug 17, 2024